Options for investigative postsurgical therapy for gastric cancer, and case report of using the option for combined immunotherapy and chemotherapy

The investigative therapy for a senior patient after radical subtotal gastr oesophagectomy for regional lymph node and proximal esophagus metastasized adenocarcinoma (stage IIIA, T3, N1, M0) of the cardioesophageal junction is reported. The case has several unusual features: (I)the patient is the aut hor and is not a physician: (2) in the absence of codified postsurgical tre atment, he used his academic biomedical background, commercial associations , and international contacts to find and prioritize six clinically tested o ptions for investigative postsurgical therapy: (3) after unsuccessful effor ts to append ongoing clinical trials of new immunotherapies for breast aden ocarcinoma (the first two therapy options), an innovative protocol was desi gned and gained allowance by the U.S. Food and Drug Administration for his use of combined nonspecific immunotherapy and chemotherapy based on extensi ve trials in South Korea that showed the synergistic effect of the two post surgical therapies used together. A potent, new, nonspecific immunostimulan t (DetoxPC) was injected subcutaneously in 10 diminishing doses during 105 weeks. Two standard chemotherapeutic drugs (5-fluorouracil and mitomycin-C) were injected intravenously in six equal doses during three weeks. Five ye ars after the surgery, the patient enjoys: good health without signs or sym ptoms of recurrence or metastasis. He discusses his perspectives on future clinical trials and on a patient actively pursuing investigative postsurgic al therapy for a malignancy when otherwise poor survival is indicated.